• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特龙基金会和意大利肌肉萎缩症防治协会,在神经肌肉健康研究方面的成功合作,为患者带来了有价值的成果。

Fondazione Telethon and Unione Italiana Lotta alla Distrofia Muscolare, a successful partnership for neuromuscular healthcare research of value for patients.

机构信息

Fondazione Telethon, Via Poerio 14, Milan, Italy.

B.E.A. Consulting, Milan, Italy.

出版信息

Orphanet J Rare Dis. 2021 Oct 2;16(1):408. doi: 10.1186/s13023-021-02047-1.

DOI:10.1186/s13023-021-02047-1
PMID:34600567
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8487484/
Abstract

In 2001, Fondazione Telethon and the Italian muscular dystrophy patient organisation Unione Italiana Lotta alla Distrofia Muscolare joined their efforts to design and launch a call for grant applications specifically dedicated to clinical projects in the field of neuromuscular disorders. This strategic initiative, run regularly over the years and still ongoing, aims at supporting research with impact on the daily life of people with a neuromuscular condition and is centred on macro-priorities identified by the patient organisation. It is investigator-driven, and all proposals are peer-reviewed for quality and feasibility. Over the years, this funding program contributed to strengthening the activities of the Italian neuromuscular clinical network, reaching many achievements in healthcare research. Moreover, it has been an enabling factor for innovative therapy experimentation at international level and prepared the clinical ground to make therapies available to Italian patients. The ultimate scope of healthcare research is to ameliorate the delivery of care. In this paper, the achievements of the funded studies are analysed also from this viewpoint, to ascertain to which extent they have fulfilled the original goals established by the patient organisation. The evidence presented indicates that this has been a highly fruitful program. Factors that contributed to its success, lessons learned, challenges, and issues that remain to be addressed are discussed to provide practical examples of an experience that could inspire also other organizations active in the field of rare disease research.

摘要

2001 年,意大利 Telethon 基金会和意大利肌肉萎缩症患者组织意大利肌肉萎缩症联合会携手合作,设计并发起了一项针对神经肌肉疾病临床项目的资助申请。这一战略倡议多年来一直定期进行,旨在支持对神经肌肉疾病患者日常生活有影响的研究,并以患者组织确定的宏观优先事项为中心。该倡议由研究人员主导,所有提案都经过同行评审,以确保其质量和可行性。多年来,该资助计划有助于加强意大利神经肌肉临床网络的活动,在医疗保健研究方面取得了许多成就。此外,它还是国际创新疗法试验的推动因素,并为意大利患者提供疗法做好了临床准备。医疗保健研究的最终目的是改善医疗服务的提供。本文还从这一角度分析了资助研究的成果,以确定它们在多大程度上实现了患者组织最初设定的目标。所提出的证据表明,这是一个非常成功的项目。本文讨论了促成该项目成功的因素、经验教训、挑战和仍然存在的问题,为其他活跃在罕见病研究领域的组织提供了一个可以借鉴的经验实例。

相似文献

1
Fondazione Telethon and Unione Italiana Lotta alla Distrofia Muscolare, a successful partnership for neuromuscular healthcare research of value for patients.特龙基金会和意大利肌肉萎缩症防治协会,在神经肌肉健康研究方面的成功合作,为患者带来了有价值的成果。
Orphanet J Rare Dis. 2021 Oct 2;16(1):408. doi: 10.1186/s13023-021-02047-1.
2
Management of motor rehabilitation in individuals with muscular dystrophies. 1 Consensus Conference report from UILDM - Italian Muscular Dystrophy Association (Rome, January 25-26, 2019).肌营养不良症患者运动康复的管理。1 UILDM-意大利肌肉萎缩症协会共识会议报告(2019 年 1 月 25 日-26 日,罗马)。
Acta Myol. 2021 Jun 30;40(2):72-87. doi: 10.36185/2532-1900-046. eCollection 2021 Jun.
3
The Italian neuromuscular registry: a coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage.意大利神经肌肉登记处:一个协调的平台,患者组织和临床医生在此合作进行数据收集和多种用途。
Orphanet J Rare Dis. 2018 Oct 4;13(1):176. doi: 10.1186/s13023-018-0918-z.
4
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
5
"Be an ambassador for change that you would like to see": a call to action to all stakeholders for co-creation in healthcare and medical research to improve quality of life of people with a neuromuscular disease.“成为你希望看到的变革的倡导者”:呼吁所有利益相关者共同参与医疗保健和医学研究,以提高患有神经肌肉疾病的人的生活质量。
Orphanet J Rare Dis. 2019 Jun 7;14(1):126. doi: 10.1186/s13023-019-1103-8.
6
Clinical trial network for the promotion of clinical research for rare diseases in Japan: muscular dystrophy clinical trial network.日本罕见病临床研究促进临床试验网络:肌营养不良临床试验网络
BMC Health Serv Res. 2016 Jul 11;16:241. doi: 10.1186/s12913-016-1477-4.
7
The positive impact on translational research of Fondazione italiana di ricerca per la Sclerosi Laterale Amiotrofica (AriSLA), a non-profit foundation focused on amyotrophic lateral sclerosis. Convergence of ex-ante evaluation and ex-post outcomes when goals are set upfront.意大利肌萎缩侧索硬化研究基金会(AriSLA)是一个专注于肌萎缩侧索硬化的非营利性基金会,其对转化研究产生了积极影响。当预先设定目标时,事前评估与事后结果的趋同。
Front Res Metr Anal. 2023 Aug 4;8:1067981. doi: 10.3389/frma.2023.1067981. eCollection 2023.
8
The struggle against neuromuscular diseases in France and the emergence of the "partnership model" of patient organisation.法国对抗神经肌肉疾病的斗争与患者组织“伙伴关系模式”的出现。
Soc Sci Med. 2003 Dec;57(11):2127-36. doi: 10.1016/s0277-9536(03)00084-4.
9
The patient experience of patient-centered communication with nurses in the hospital setting: a qualitative systematic review protocol.医院环境中患者与护士以患者为中心的沟通体验:一项定性系统评价方案
JBI Database System Rev Implement Rep. 2015 Jan;13(1):76-87. doi: 10.11124/jbisrir-2015-1072.
10
Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome.2023 年多囊卵巢综合征评估和管理国际循证指南推荐意见。
Fertil Steril. 2023 Oct;120(4):767-793. doi: 10.1016/j.fertnstert.2023.07.025. Epub 2023 Aug 14.

本文引用的文献

1
Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy.意大利遗传性转甲状腺素淀粉样变性(ATTRv)患者及其亲属的心理社会负担和专业及社会支持。
Orphanet J Rare Dis. 2021 Apr 7;16(1):163. doi: 10.1186/s13023-021-01812-6.
2
Disease monitoring programs of rare genetic diseases: transparent data sharing between academic and commercial stakeholders.罕见遗传病的疾病监测项目:学术和商业利益相关者之间透明的数据共享。
Orphanet J Rare Dis. 2021 Mar 20;16(1):141. doi: 10.1186/s13023-021-01687-7.
3
Recommendations for pre-symptomatic genetic testing for hereditary transthyretin amyloidosis in the era of effective therapy: a multicenter Italian consensus.
针对有效治疗时代遗传性转甲状腺素蛋白淀粉样变性症的无症状前基因检测的建议:一项多中心意大利共识。
Orphanet J Rare Dis. 2020 Dec 14;15(1):348. doi: 10.1186/s13023-020-01633-z.
4
Large genotype-phenotype study in carriers of D4Z4 borderline alleles provides guidance for facioscapulohumeral muscular dystrophy diagnosis.对D4Z4临界等位基因携带者进行的大型基因型-表型研究为面肩肱型肌营养不良症的诊断提供了指导。
Sci Rep. 2020 Dec 10;10(1):21648. doi: 10.1038/s41598-020-78578-7.
5
Pregnancy in Charcot-Marie-Tooth disease: Data from the Italian CMT national registry.Charcot-Marie-Tooth 病患者的妊娠情况:来自意大利 CMT 国家注册中心的数据。
Neurology. 2020 Dec 15;95(24):e3180-e3189. doi: 10.1212/WNL.0000000000010860. Epub 2020 Sep 14.
6
FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development.美国食品和药物管理局孤儿产品临床试验资助:对结果的评估及其对罕见病产品开发的影响。
Orphanet J Rare Dis. 2020 Sep 3;15(1):234. doi: 10.1186/s13023-020-01514-5.
7
A 5-year clinical follow-up study from the Italian National Registry for FSHD.来自意大利 FSHD 国家登记处的一项为期 5 年的临床随访研究。
J Neurol. 2021 Jan;268(1):356-366. doi: 10.1007/s00415-020-10144-7. Epub 2020 Aug 19.
8
ATTRv amyloidosis Italian Registry: clinical and epidemiological data.ATTR 淀粉样变意大利登记处:临床和流行病学数据。
Amyloid. 2020 Dec;27(4):259-265. doi: 10.1080/13506129.2020.1794807. Epub 2020 Jul 22.
9
Suitability of external controls for drug evaluation in Duchenne muscular dystrophy.用于杜氏肌营养不良症药物评估的外部对照的适宜性。
Neurology. 2020 Sep 8;95(10):e1381-e1391. doi: 10.1212/WNL.0000000000010170. Epub 2020 Jul 1.
10
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey?脊髓性肌萎缩症的诊断之旅:是否仍充满曲折?
PLoS One. 2020 Mar 23;15(3):e0230677. doi: 10.1371/journal.pone.0230677. eCollection 2020.